Centessa Pharmaceuticals (NASDAQ:CNTA) Given “Equal Weight” Rating at Wells Fargo & Company

Centessa Pharmaceuticals (NASDAQ:CNTA)‘s stock had its “equal weight” rating reissued by equities research analysts at Wells Fargo & Company in a note issued to investors on Monday,Benzinga reports. They presently have a $42.00 price target on the stock, up from their previous price target of $35.00. Wells Fargo & Company‘s price target suggests a potential upside of 6.03% from the stock’s previous close.

CNTA has been the topic of several other reports. Lifesci Capital lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 1st. Piper Sandler reissued an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Stephens lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Leerink Partners downgraded Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and lifted their target price for the company from $36.00 to $40.00 in a research report on Wednesday, April 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Four investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $40.70.

Centessa Pharmaceuticals Stock Down 0.1%

CNTA stock traded down $0.05 during trading on Monday, reaching $39.61. 819,934 shares of the company traded hands, compared to its average volume of 2,431,604. The business has a 50 day simple moving average of $30.15 and a 200 day simple moving average of $26.76. The company has a debt-to-equity ratio of 0.21, a quick ratio of 8.57 and a current ratio of 8.57. Centessa Pharmaceuticals has a 12 month low of $10.95 and a 12 month high of $40.26. The company has a market capitalization of $6.12 billion, a price-to-earnings ratio of -26.95 and a beta of 1.25.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.10). On average, equities research analysts anticipate that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Iqbal J. Hussain sold 38,951 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the completion of the transaction, the insider directly owned 57,645 shares of the company’s stock, valued at $1,449,771.75. This trade represents a 40.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Karen M. Anderson sold 41,076 shares of the stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the sale, the insider owned 62,085 shares in the company, valued at approximately $1,870,000.20. This trade represents a 39.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 349,073 shares of company stock valued at $9,429,412. 7.09% of the stock is owned by company insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Millennium Management LLC boosted its holdings in Centessa Pharmaceuticals by 52.9% in the first quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock valued at $8,760,000 after acquiring an additional 210,737 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Centessa Pharmaceuticals during the first quarter worth about $2,176,000. Geode Capital Management LLC increased its position in shares of Centessa Pharmaceuticals by 44.7% during the second quarter. Geode Capital Management LLC now owns 87,435 shares of the company’s stock worth $1,149,000 after acquiring an additional 26,994 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Centessa Pharmaceuticals by 155.4% in the second quarter. JPMorgan Chase & Co. now owns 428,434 shares of the company’s stock valued at $5,630,000 after buying an additional 260,702 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in Centessa Pharmaceuticals by 29.2% during the second quarter. Legal & General Group Plc now owns 98,256 shares of the company’s stock valued at $1,291,000 after purchasing an additional 22,205 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.